# US 2023/0068460 A1 · Prophylactic uses of annexin a2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068460 A1
- Document ID: US20230068460A1
- Status: Published application
- Kind: A1
- Application number: 17/797,663
- Filed: 2021-02-04
- Published: 2023-03-02
- Earliest claimed: 2020-02-04
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, a body corporate
- Inventors: Zhirui Wang; Ernest Moore
- Web page: https://patentgrep.com/patent/US20230068460A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/166: {Streptokinase}
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/745: Blood coagulation or fibrinolysis factors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Curative and prophylactic therapies for microvascular and/or macrovascular thrombosis are provided, as are prophylactic therapies capable of preventing fibrinolysis shutdown and therapies for non-thrombotic disorders. Methods provide for administering a therapeutically effective amount of an annexin A2.

## Claims

### Claim 1

A method of dissolving clot formation in a subject, comprising administering to the subject a therapeutically effective amount of an annexin A2.

### Claim 2 (depends on 1)

The method of claim 1, wherein in the subject is selected as a candidate for thromboprophylaxis therapy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has fibrinolytic shutdown or is at risk of fibrinolytic shutdown.

### Claim 4 (depends on 1)

The method of claim 1, wherein the annexin A2 is a wild-type annexin A2 or a recombinant annexin A2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the annexin A2 is a recombinant annexin A2 comprising a conservative substitution mutation at position N62, at position S64, or at both position N62 and S64, wherein the conservative substitution mutation is relative to SEQ ID NO: 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the conservative substitution mutation at N62 is N62A or N62G, and the conservative substitution at S64 is S64A or S64G.

### Claim 7 (depends on 1)

The method of claim 1, wherein the annexin A2 is an annexin A2 comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effective amount of annexin A2 is between about 0.1 mg/kg to about 5 mg/kg.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering to the subject a therapeutically effective amount of one or more fibrinolytics.

### Claim 10 (depends on 9)

The method of claim 9, wherein the one or more fibrinolytics are selected from the group consisting of: streptokinase, urokinase, anistreplase, alteplase, reteplase, and tenecteplase.

### Claim 11

A method of treating, preventing, or slowing progression of a non-thrombotic disorder of fibrin deposition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an annexin A2.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has acute respiratory distress syndrome, acute kidney injury, liver failure, or encapsulating peritoneal sclerosis.

### Claim 13 (depends on 11)

The method of claim 11, wherein the annexin A2 is a wild-type annexin A2 or a recombinant annexin A2.

### Claim 14 (depends on 11)

The method of claim 11, wherein the annexin A2 is a recombinant annexin A2 comprising a conservative substitution mutation at position N62, at position S64, or at both position N62 and S64, wherein the conservative substitution mutation is relative to SEQ ID NO: 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the conservative substitution mutation at N62 is N62A or N62G, and the conservative substitution at S64 is S64A or S64G.

### Claim 16 (depends on 11)

The method of claim 11, wherein the annexin A2 is an annexin A2 comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

### Claim 17 (depends on 11)

The method of claim 11, wherein the effective amount of annexin A2 is between about 0.1 mg/kg to about 5 mg/kg.

### Claim 18 (depends on 11)

The method of claim 11, further comprising administering to the subject a therapeutically effective amount of one or more fibrinolytics.

### Claim 19 (depends on 18)

The method of claim 18, wherein the one or more fibrinolytics are selected from the group consisting of: streptokinase, urokinase, anistreplase, alteplase, reteplase, and tenecteplase.

### Claim 20

A method of enhancing clot dissolution in a subject, comprising administering to the subject a therapeutically effective amount of an annexin A2.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject is selected as a candidate for fibrinolytic therapy.

### Claim 22 (depends on 20)

The method of claim 20, wherein the subject has fibrinolytic shutdown.

### Claim 23 (depends on 20)

The method of claim 20, wherein the annexin A2 is a wild-type annexin A2 or a recombinant annexin A2.

### Claim 24 (depends on 20)

The method of claim 20, wherein the annexin A2 is a recombinant annexin A2 comprising a conservative substitution mutation at position N62, at position S64, or at both position N62 and S64, wherein the conservative substitution mutation is relative to SEQ ID NO: 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the conservative substitution mutation at N62 is N62A or N62G, and the conservative substitution at S64 is S64A or S64G.

### Claim 26 (depends on 20)

The method of claim 20, wherein the annexin A2 is an annexin A2 comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:
3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

### Claim 27 (depends on 20)

The method of claim 20, wherein the effective amount of annexin A2 is between about 0.1 mg/kg to about 5 mg/kg.

### Claim 28 (depends on 20)

The method of claim 20, further comprising administering to the subject a therapeutically effective amount of one or more fibrinolytics.

### Claim 29 (depends on 28)

The method of claim 28, wherein the one or more fibrinolytics are selected from the group consisting of: streptokinase, urokinase, anistreplase, alteplase, reteplase, and tenecteplase.
